Recombinant Human EPHB4 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg6504
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human EPHB4 protein Leu16-Ala539 (Accession# P54760) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 2050 |
| Accession | P54760 |
| PredictedSize | 83.1 kDa |
| SDS-PAGE | 83-100 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
EPHB4 (Ephrin type-B receptor 4), a member of the largest family of receptor tyrosine kinases (RTK), is overexpressed in several tumor types, including prostate, breast, and bladder tumors and down-regulation of EPHB4 in tumor cell lines of these origins results in reduced cell viability, migration, and invasion. In endothelial cells, where EphB4 is normally expressed, it regulates cell migration, proliferation, and invasion. The discovery of EphB4 as an alternative Epo receptor has multiple clinical implications including opportunities for patient stratification and anti-EphB4 approaches to abrogate the stimulatory effects of Epo on tumor growth.
References:
1. Xia, Guangbin et al. Cancer research vol. 65,11 (2005): 4623-32. 2. Davalos, Veronica et al. Cancer research vol. 66,18 (2006): 8943-8. 3. Erber, Ralf et al. The EMBO journal vol. 25,3 (2006): 628-41.